A non-comparative, randomized, phase II trial of atezolizumab or atezolizumab plus tiragolumab for programmed death-ligand 1-positive recurrent cervical cancer (SKYSCRAPER-04)

Ritu Salani, Mary McCormack, Yong‐Man Kim, Sharad Ghamande, Shaundra L. Hall, Domenica Lorusso, Lisa Barraclough, Lucy Gilbert, Adrián Guzmán Ramírez, Chien‐Hsing Lu, Renaud Sabatier, Nicoletta Colombo, Youyou Hu, Venkatesh Krishnan, Luciana Molinero, Yuning Feng, Nicole J. Kim, Marcela Castro, Yvonne G. Lin, Bradley J. Monk